Department of Psychiatry and Psychotherapy, Charité Campus Mitte, Universitätsmedizin Berlin, Germany.
Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):687-93. doi: 10.1002/pds.1976.
Pharmacological treatment is used in patients with somatoform disorders (SD) although the empirical evidence is scarce. We evaluated the current pharmacological treatment strategies used for psychiatric in-patients diagnosed with SD in Central Europe.
Cross-sectional data of the pharmacological treatment, age, gender, and the primary psychiatric diagnosis of 70,566 in-patients were collected on 2 days in April and October of the years 1994-2006 in 57 psychiatric hospitals and departments.
Three hundred fifty nine patients corresponding to 0.51% of the psychiatric in-patient population were hospitalized for SD. 94.7% of the SD patients received psychopharmacological treatment including antidepressants (78.2%), neuroleptics (43.3%), tranquilizers (22.6%), hypnotics (15.6%), and anticonvulsants (12.3%). 61.3% were treated with psychotropic combinations, most commonly antidepressant and neuroleptic (36.2%). In addition, 63.7% received one or multiple somatic medications.
As compared to general medical and neurological in-patient populations, SD patients represent a small proportion of the psychiatric in-patient population. They commonly receive multiple psychotropic and somatic medications. The psychotropics used have predominantly sedating characteristics.
SD patients are at risk of polypharmacy in psychiatry.
躯体形式障碍（SD）患者常接受药物治疗，但经验证据有限。我们评估了中欧地区精神科住院患者中 SD 的当前药物治疗策略。
在 1994 年至 2006 年的 4 月和 10 月的两天内，收集了 57 家精神病院和部门中 70566 名住院患者的药物治疗、年龄、性别和主要精神诊断的横断面数据。
359 名患者（占精神科住院患者的 0.51%）因 SD 住院。94.7%的 SD 患者接受了精神药理学治疗，包括抗抑郁药（78.2%）、神经阻滞剂（43.3%）、镇静剂（22.6%）、催眠药（15.6%）和抗惊厥药（12.3%）。61.3%的患者接受了精神药物联合治疗，最常见的是抗抑郁药和神经阻滞剂（36.2%）。此外，63.7%的患者接受了一种或多种躯体药物治疗。
与一般内科和神经科住院患者相比，SD 患者在精神科住院患者中所占比例较小。他们通常接受多种精神药物和躯体药物治疗。使用的精神药物主要具有镇静作用。
SD 患者在精神科中存在药物滥用的风险。
